A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms
Latest Information Update: 02 Jul 2025
At a glance
- Drugs Gabapentin/nabilone PleoPharma (Primary) ; Gabapentin; Nabilone
- Indications Substance-related disorders
- Focus Therapeutic Use
- Sponsors PleoPharma
Most Recent Events
- 19 Jun 2025 Results presented in the PleoPharma Media Release.
- 19 Jun 2025 According to a PleoPharma, Inc. media release, the company presented a poster presentation on June 17, 2025 and an oral presentation on June 18, 2025 from this trial at the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, LA.
- 13 Feb 2025 According to a PleoPharma, Inc. media release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 for the mitigation of Cannabis Withdrawal Syndrome in patients with Cannabis Use Disorder.